The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
Min Pan(St. Jude Children's Research Hospital), Paul Geeleher(St. Jude Children's Research Hospital), Manbir Sandhu(St. Jude Children's Research Hospital), Taosheng Chen(St. Jude Children's Research Hospital), Jake E. Batchelder(St. Jude Children's Research Hospital), Darcie J. Miller(St. Jude Children's Research Hospital), Shondra M. Pruett‐Miller(St. Jude Children's Research Hospital), Scott C. Blanchard(University of California, Santa Cruz), Michael A. Dyer(St. Jude Children's Research Hospital), John Easton(St. Jude Children's Research Hospital), Asif Zubair(St. Jude Children's Research Hospital), Jon P. Connelly(St. Jude Children's Research Hospital), Rich Chapple(St. Jude Children's Research Hospital), Payton Archer(St. Jude Children's Research Hospital), Samuel W. Brady(St. Jude Children's Research Hospital), Burgess B. Freeman(St. Jude Children's Research Hospital), John D. Schuetz(St. Jude Children's Research Hospital), Brittney Gordon(St. Jude Children's Research Hospital), Lucy A. Godley(University of Chicago), William C. Wright(St. Jude Children's Research Hospital), Matthew J. Posgai(University of Chicago), Siquan Chen, Jonathan Low(St. Jude Children's Research Hospital), Yingzhe Wang(University of Mississippi), Elizabeth Stewart(St. Jude Children's Research Hospital), M. Madan Babu(St. Jude Children's Research Hospital), Ravi Kalathur(St. Jude Children's Research Hospital), Kaley Blankenship(St. Jude Children's Research Hospital), Sivaraman Natarajan(St. Jude Children's Research Hospital)
Cited by 6
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k